Shots:

• BIOEQ will sponsor the P-III study which will assess the FYB203 vs Eylea in patients with neovascular age-related macular degeneration (nAMD) to evaluate its efficacy- safety and immunogenicity. Additionally- the design of the study is developed in collaboration with the USFDA- EMA- PMDA
• The second program in ophthalmology will aim to strengthen and expand the footprints in ophthalmologic biosimilars
• FYB203 is a biosimilar to Eylea (aflibercept) human fusion protein works by binding to VEGF-A- targeted for neovascular age-related macular degeneration (nAMD) including serious eye diseases. In 2015- Formycon AG signed an exclusive global license agreement with Santo Holding (Deutschland) GmbH for FYB203

Ref: Formycon | Image: Behance